Blood pressure effects of SGLT2 inhibitors in kidney transplant recipients: a systematic review and meta-analysis.
Int Urol NephrolApr 29, 2026 (epub)
Abdullah Ahmad, Muhammad Hasnain Mankani, Abdullah Al-Kahil et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of SGLT2 inhibitors on blood pressure in kidney transplant recipients. Analyzing data from 12 studies with 1,292 participants, the study found no significant reductions in blood pressure compared to control groups at any time point. Exploratory analyses indicated potential short-term reductions in systolic blood pressure, but these findings are at high risk of bias.
Key findings
- No significant blood pressure reductions were observed with SGLT2 inhibitors compared to control at any time point.
- Exploratory analyses suggested modest reductions in systolic blood pressure at 3 and 6 months.
- The safety profile of SGLT2 inhibitors was deemed acceptable in the studied population.
Why it matters
Understanding the impact of SGLT2 inhibitors on blood pressure in kidney transplant recipients is crucial, as hypertension is a common complication that can affect cardiovascular health and allograft function.